Wuhan YZY Biopharma Past Earnings Performance
Past criteria checks 0/6
Wuhan YZY Biopharma has been growing earnings at an average annual rate of 1.2%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 2.2% per year.
Key information
1.2%
Earnings growth rate
7.4%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 2.2% |
| Return on equity | -370.1% |
| Net Margin | -2,275.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Wuhan YZY Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 8 | -184 | 27 | 154 |
| 31 Mar 24 | 10 | -188 | 25 | 154 |
| 31 Dec 23 | 12 | -192 | 22 | 155 |
| 30 Sep 23 | 10 | -189 | 22 | 151 |
| 30 Jun 23 | 8 | -186 | 21 | 147 |
| 31 Mar 23 | 5 | -187 | 21 | 152 |
| 31 Dec 22 | 2 | -189 | 21 | 157 |
| 31 Dec 21 | 12 | -149 | 31 | 113 |
Quality Earnings: 2496 is currently unprofitable.
Growing Profit Margin: 2496 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2496's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2496's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2496 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 2496 has a negative Return on Equity (-370.1%), as it is currently unprofitable.